V L represents alveolar volume. Lower case c is the displacement of CO 2 fraction away 31 from its mean value C . Likewise lower case v represents the displacement of alveolar 32 ventilation from its mean value A V . Because of the time delay, the value of v at time t 33 (v t ) depends on the value of c at some time δ previously (c (t-δ) ). Near the steady state, 34 therefore, v t = S x c (t-δ) , where S represents chemoreflex gain (additional ventilation 35 per unit increase in c). We adopted the convention of using litres for all volumes, and 36 minutes for all times. 37
The terms in the above equation represent flow of CO 2 into and out of the lung arising 38 from metabolism, ventilation, and exchange with blood stores. Metabolic production 39 of CO 2 by the body is expressed as C VA . The rate of CO 2 removal from the lung by 40 ventilation is expressed as ( A V + v) ( C + c). Oscillations in arterial CO 2 necessitate a 41 net transfer of CO 2 from the lung into extra pulmonary stores (in comparison with the 42 steady state) at a rate of β Q c, where β indicates the solubility of CO 2 in blood and Q , 43 cardiac output, assuming that pulmonary venous CO 2 is stable. 44
For the purpose of our numerical model we define the instantaneous alveolar CO 2 45 fraction and ventilation as upper case C and V respectively, where C= C + c, and 46 V= A V + v. We also define the rate of metabolic production of CO 2 as Vco 2 , where 47
Vco 2 = C VA . Therefore, the above equation can be rewritten as: 48
The mean value of CO 2 fraction C is not time-variant, i.e. d C /dt = 0. Hence, the 50 change in instantaneous alveolar CO 2 fraction over the small time step Δt can be 51 written as Equation 4 in the main manuscript: 52
We used 1 second steps for the model. We investigated whether a change in the time 54 step had any effect in the model output, to ensure that the model is not affected by 55 numerical instability instead of system instability (due to large time steps). We ran the 56 simulation with time steps of 0.1, 0.5, 1, 5, and 10 seconds. We found no difference in 57 stability for time steps of 1 second or less. Numerical instability was observed when 58 the time steps were 5 seconds or more. 59
Sensitivity analysis 60
We further analyzed the sensitivity of the model using extreme (minimum and 61 maximum) values of its parameters as follows: chemoreflex delay (0.28 and 0.67 62 min), cardiac output (2.5 and 4.5 l/min), chemoreflex gain (1100 and 1800 l/min/atm), 63 metabolic production of CO 2 (0.1 and 0.4 l/min) and lung volume (3 and 6 l). These 64 values were based on previous observations on heart failure patients with periodic 65 breathing (reference 12 in the main manuscript). We ran simulations on all the 32 (= 66 2 5 ) possible combinations of these extreme cases using 2% peak concentration and 67 180 degrees duration of treatment episode within the periodic breathing cycle. 68
We measured the magnitude of periodic breathing, i.e. standard deviation of 69 ventilation, before treatment in all the combinations. We measured the optimumWe measured the optimum phase, i.e. the phase of treatment at which we obtained the 73 optimum relative periodic breathing value. We also measured the margin of error for 74 the optimum phase (the window of treatment phase at which periodic breathing is 75 reduced by at least 30%). 76
Twenty six of the thirty two combinations were unstable; the remaining six produced 77 a stable or too small ventilatory oscillation pattern to initiate treatment episodes; 78 hence there were no optimum treatment regions in these cases. Nineteen of the twenty 79 six unstable combinations responded to the default treatment regime shape (2% peak 80 concentration and 180 degrees duration of treatment episode within the periodic 81 breathing cycle). The remaining seven of these unstable combinations did not respond 82 significantly to the above treatment regime; a change in peak concentration (other 83 than 2%) and/or a change in duration of treatment episode within the periodic 84 breathing cycle (other than 180 degrees) was needed to generate a reduction of >20% 85 in periodic breathing. Even in these cases the region of optimal treatment phase was 86 unchanged. For simplicity we have tabulated the results of the simulations that 87 generated oscillations and responded to the default treatment regime shape because 88 these are directly mutually comparable (Table S-1) . 89
We performed factor analysis with these data, using Design-Expert software (revision 90 7.1.6). We found that the optimum treatment phase is mainly dictated by the 91 chemoreflex delay as shown in Figure S -1. The optimum treatment phase for periodic 92 breathing with shorter chemoreflex delays lay ahead of the peak ventilation whereas 93 periodic breathing with longer delays lay later than peak ventilation. We also noted 94
Standard deviation of ventilation after treatment Standard deviation of ventilation before treatment that larger lung volumes shifted the optimum treatment phase slightly later in the 95 cycle (by 20 degrees for the variation of 3-6 litres). 96
Extreme changes in the various physiological parameters can affect how well the 97 model responds to a particular dosing regime (i.e. the optimum relative periodic 98 breathing value and margin of error at the optimum treatment phase), but these 99 outcomes are not directly correlated to any particular physiological variable. 100 Table S 
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The optimum treatment phase is notably affected by the chemoreflex delay and to a lesser extent the lung volume,
110
but not by cardiac output, chemoreflex gain and the metabolic production rate of CO2.
111

Effect of peak concentration and treatment duration 112
By varying both duration and concentration, it is possible to produce a 3-dimensional 113 (3D) representation of efficacy of treatment. Figure S- 
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The periodic breathing can be worsened (areas shaded orange and red) as well as improved (areas shaded green 
